MetabolicInvestigational

Peptide YY

A satiety-linked gut hormone that has long been studied in obesity and appetite regulation.

Gut HormoneSatietyObesityInvestigational

Also referenced as: PYY, PYY3-36

Also appears in: Hormone

Public product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area
Metabolic / incretin research

Primary research area: Metabolic. Also surfaces under Hormone for browsing and discovery.

Aliases
2

PYY, PYY3-36

Signal depth
Medium

No FDA label signal · 715 trials · 4406 PubMed results

Promising
Research evidence

Peptide YY has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Peptide YY has 3 name-matched clinical trials (highest phase: Phase 2) and 4406 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 2
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
PHASE2 · RandomizedCo-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in BulimiaPHASE1/PHASE2 · RandomizedInhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36NA · RandomizedProtein Dose-repsonse Effect on GLP-1, PYY and Appetite in Male SubjectsNature · 2,346 citationsGut hormone PYY3-36 physiologically inhibits food intakeNature · 2,284 citationsNeuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptideNew England Journal of Medicine · 1,591 citationsInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Evidence history
  1. 2026-09-01Preclinical→PromisingBand Preclinical → Promising; +22 trials
  2. 2026-08-25Promising→PreclinicalBand Promising → Preclinical; -14 trials; +1 PubMed
  3. 2026-08-22Early→PromisingBand Early → Promising; -8 trials
  4. 2026-08-21Promising→EarlyBand Promising → Early; +8 trials
  5. 2026-08-19Preclinical→PromisingBand Preclinical → Promising; +21 trials
  6. 2026-08-18Early→PreclinicalBand Early → Preclinical; -21 trials
  7. 2026-08-14Promising→EarlyBand Promising → Early; -15 trials
  8. 2026-08-13Preclinical→PromisingBand Preclinical → Promising; +22 trials; +1 PubMed
  9. 2026-08-12Promising→PreclinicalBand Promising → Preclinical; -14 trials
  10. 2026-08-11Preclinical→PromisingBand Preclinical → Promising; +14 trials; +1 PubMed
  11. 2026-08-05Early→PreclinicalBand Early → Preclinical
  12. 2026-08-01Promising→EarlyBand Promising → Early; -7 trials; +2 PubMed
  13. 2026-07-28Preclinical→PromisingBand Preclinical → Promising; +15 trials; +2 PubMed
  14. 2026-07-25Early→PreclinicalBand Early → Preclinical; -7 trials; +3 PubMed
  15. 2026-07-24Promising→EarlyBand Promising → Early; +14 trials
  16. 2026-07-22Preclinical→PromisingBand Preclinical → Promising; +29 trials

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What peptide YY is

Peptide YY, often shortened to PYY, is a satiety-linked gut hormone involved in appetite regulation.

Why it matters

PYY belongs in any serious obesity-peptide library because it is part of the physiological foundation behind modern appetite-control pharmacology.

Regulatory context

Peptide YY is not FDA approved as a standard peptide therapy in the United States.

Practical reading note

PYY is one of those peptides that matters scientifically even when later drug development ends up using more stable analogs or combinations instead of the native hormone itself.